175 related articles for article (PubMed ID: 14641514)
21. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; van den Berg LH; Vermeulen M; Brusse E; Cats EA; van der Kooi AJ; Notermans NC; van der Pol WL; van Schaik IN; van Nes SI; Hop WC; van Doorn PA
J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1374-9. PubMed ID: 20587484
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of the OSAC randomised controlled trial: oral corticosteroids for non-asthmatic adults with acute lower respiratory tract infection in primary care.
Moure-Fernandez A; Hollinghurst S; Carroll FE; Downing H; Young G; Brookes S; May M; El-Gohary M; Harnden A; Kendrick D; Lafond N; Little P; Moore M; Orton E; Thompson M; Timmins D; Wang K; Hay AD
BMJ Open; 2020 Feb; 10(2):e033567. PubMed ID: 32075830
[TBL] [Abstract][Full Text] [Related]
23. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.
Mendell JR; Barohn RJ; Freimer ML; Kissel JT; King W; Nagaraja HN; Rice R; Campbell WW; Donofrio PD; Jackson CE; Lewis RA; Shy M; Simpson DM; Parry GJ; Rivner MH; Thornton CA; Bromberg MB; Tandan R; Harati Y; Giuliani MJ;
Neurology; 2001 Feb; 56(4):445-9. PubMed ID: 11222785
[TBL] [Abstract][Full Text] [Related]
24. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
[TBL] [Abstract][Full Text] [Related]
25. Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study).
Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA
J Peripher Nerv Syst; 2018 Mar; 23(1):5-10. PubMed ID: 29119642
[TBL] [Abstract][Full Text] [Related]
26. Home versus hospital immunoglobulin treatment for autoimmune neuropathies: A cost minimization analysis.
Le Masson G; Solé G; Desnuelle C; Delmont E; Gauthier-Darnis M; Puget S; Durand-Zaleski I
Brain Behav; 2018 Feb; 8(2):e00923. PubMed ID: 29484273
[TBL] [Abstract][Full Text] [Related]
27. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.
Lazzaro C; Lopiano L; Cocito D
Neurol Sci; 2014 Jul; 35(7):1023-34. PubMed ID: 24469345
[TBL] [Abstract][Full Text] [Related]
28. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.
Gherardi A; Roze S; Kuijvenhoven J; Ghatnekar O; Yip Sonderegger YL
J Med Econ; 2018 Sep; 21(9):869-877. PubMed ID: 29857775
[TBL] [Abstract][Full Text] [Related]
29. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
Hughes RA; Donofrio P; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Latov N; Merkies IS; van Doorn PA;
Lancet Neurol; 2008 Feb; 7(2):136-44. PubMed ID: 18178525
[TBL] [Abstract][Full Text] [Related]
30. Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial.
Mason JM; Thomas KS; Ormerod AD; Craig FE; Mitchell E; Norrie J; Williams HC;
Br J Dermatol; 2017 Dec; 177(6):1527-1536. PubMed ID: 28391619
[TBL] [Abstract][Full Text] [Related]
31. Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes.
Breiner A; Barnett Tapia C; Lovblom LE; Perkins BA; Katzberg HD; Bril V
Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):. PubMed ID: 31454771
[TBL] [Abstract][Full Text] [Related]
32. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.
Hughes RA
Expert Rev Neurother; 2009 Jun; 9(6):789-95. PubMed ID: 19496683
[TBL] [Abstract][Full Text] [Related]
33. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
34. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
[TBL] [Abstract][Full Text] [Related]
35. Relapse with Dysphagia in a Case of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Teramoto H; Morita A; Hara M; Ninomiya S; Shigihara S; Kusunoki S; Kamei S
Intern Med; 2015; 54(14):1791-3. PubMed ID: 26179538
[TBL] [Abstract][Full Text] [Related]
36. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes RA; Mehndiratta MM
Cochrane Database Syst Rev; 2012 Aug; (8):CD002062. PubMed ID: 22895925
[TBL] [Abstract][Full Text] [Related]
37. Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
Adrichem ME; Lucke IM; Vrancken AFJE; Goedee HS; Wieske L; Dijkgraaf MGW; Voermans NC; Notermans NC; Faber CG; Visser LH; Kuitwaard K; van Doorn PA; Merkies ISJ; de Haan RJ; van Schaik IN; Eftimov F
Brain; 2022 Jun; 145(5):1641-1652. PubMed ID: 35139161
[TBL] [Abstract][Full Text] [Related]
38. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial.
van Schaik IN; Eftimov F; van Doorn PA; Brusse E; van den Berg LH; van der Pol WL; Faber CG; van Oostrom JC; Vogels OJ; Hadden RD; Kleine BU; van Norden AG; Verschuuren JJ; Dijkgraaf MG; Vermeulen M
Lancet Neurol; 2010 Mar; 9(3):245-53. PubMed ID: 20133204
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
[TBL] [Abstract][Full Text] [Related]
40. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.
Briggs AH; Lozano-Ortega G; Spencer S; Bale G; Spencer MD; Burge PS
Value Health; 2006; 9(4):227-35. PubMed ID: 16903992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
